eligibility_summary
Adults ≥18 with early-stage MF (CTCL IA–IIA), positive TCR (B0/B1), any prior therapy, SD/PR/PD after ≥3 mo phototherapy (± topicals), 14‑day washout, ECOG 0–1, adequate labs, stable low‑dose steroids/topicals allowed, prior mogamulizumab OK if CR >1 yr. Exclude: current LCT, active infections (HIV/HTLV/HBV/HCV, herpes), recent surgery/radiation, recent malignancy, pregnancy/breastfeeding (contraception required), uncontrolled illness (cardiac, etc.), autoimmune disease, mAb allergy/HSCT, immunomodulators, photosensitizers/photosensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
PLIGHT (NCT06235281) tests POTELIGEO (mogamulizumab-kpkc) plus narrow-band UVB phototherapy in early-stage mycosis fungoides. Mogamulizumab is an afucosylated humanized IgG1 monoclonal antibody (immunotherapy) targeting CCR4 on malignant skin-homing T cells and regulatory T cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and disrupting CCR4/CCL17–CCL22 chemokine signaling and trafficking. Phototherapy (nb-UVB, device) induces apoptosis of cutaneous T cells and immunomodulates the skin microenvironment. Targets/pathways: CCR4+ MF cells, Tregs, CCR4 axis, UVB-induced apoptotic pathways in skin T cells.